Fulgent Genetics (FLGT) Liabilities and Shareholders Equity (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $1.2 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 4.09% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 billion (down 2.2% YoY) and the FY2025 annual result came in at $1.2 billion, down 0.53% from the prior year.
• Liabilities and Shareholders Equity slipped to $1.2 billion in Q1 2026 per FLGT's latest filing, from $1.2 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.5 billion in Q1 2022, with the low at $93.2 million in Q4 2022.
• Average Liabilities and Shareholders Equity over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity sank 92.71% in 2022 and surged 1225.0% in 2023.
• Fulgent Genetics' Liabilities and Shareholders Equity stood at $93.2 million in 2022, then surged by 1225.0% to $1.2 billion in 2023, then fell by 1.24% to $1.2 billion in 2024, then dropped by 0.53% to $1.2 billion in 2025, then decreased by 4.71% to $1.2 billion in 2026.
• Business Quant data shows FLGT's Liabilities and Shareholders Equity at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.2 billion in Q3 2025.